Is there anyone at #ASCO22, or not, who thinks hotel door bag drop of pharma advertisements is anything but a tone-deaf, disdainful waste of money & paper?
To me, it symbolizes an utter lack of ability to adapt to changing times. Don't highlight you're dinosaurs in an Ice Age.
H. Jack West, MD, FASCO
27K posts
VP of Global Medical Affairs @SMMT_Tx; Founder,@CancerGRACE; fmr author/ed @UptoDate. Tech-friendly for an old guy. Likes/RTs ≠ endorsement
- 🚨 Big changes afoot! I'm proud to announce that I've joined Summit Therapeutics (@summitplc) as VP of Clinical Development! I look forward to my colleagues learning more about the company & ivonescimab. No more commentary from me on new data, but I'll contribute as I can.
- KRAS G12C inhibitor sotorasib combined with pembrolizumab for KRAS G12C+ adv NSCLC led to prohibitive hepatotoxicity that required aggressive dose reduction of sotorasib. We've seen similar probs with some other targeted therapies combined w/immunotherapies. #WCLC22
- I'm not sure I can envision a more intellectually dishonest figure than one that has the y-axis extend from 99 to 100 to show a huge separation of curves. 🙄 Really misrepresents the actual findings.Psoriasis Risk With Immune Checkpoint Inhibitors @JAMADerm doi.org/10.1001/jamade… ❓What is the risk to develop psoriasis with ICI 🔎135 230 pts 👉2-fold increased, 0.5 vs 0.2% 🧐Uncommon, but be aware & provide optimal care @myESMO
- Replying to @Tony_Calles @BrendonStilesMD and 8 othersNot current. My quick algorithm: 1) Check driver mut'ns & PD-L1 2) if EGFR, ALK, ROS1, or BRAF V600E+ -> targeted Rx 3) o/w, if PD-L1 <50% -> chemo/IO (KN189 for nonsquam, KN407 for squam); if PD-L1 > or =50%, pembro mono unless high tumor burden/declining PS (if so, chemo/IO 1L)
- Dr. R. Govindan presents update on ph1 of KRAS G12C mut’n inhib AMG 510 in NSCLC. Impressive results: well tolerated, w/no DLTs up to 960 mg QD; DCR 96%, ORR 48% in evaluable pts. IMO, this is a turning point of effective Rx against tough & common mut’n. #WCLC19 #OncoAlert #LCSM
- Amazing & wonderful to see median surv out at 30+ mo for pts w/high tumor PD-L1 receiving 1st line pembro. That's 28-30% of pts who add to those w/driver mut'ns, & it means we're at point where we're nearing a majority of pts w/adv NSCLC having expectation of living years. #LCSMUpdated analysis of KEYNOTE-024 - pembrolizumab vs platinum-based chemo for advanced NSCLC bit.ly/2LUcZ3W #lcsm #immunoonc
- Celebrating my lovely wife's birthday tonight. 🎂🎈For the record, I didn't marry someone 25 years younger than me. Amazingly, we're the same age, but no question who wears it better.
- My wife & I are thinking of getting away this weekend, spending it in our guest room for a change of pace.
- I'm so tired of having to reschedule patients for further days out after the lab fails to deliver molecular marker results in the expected time. 😞 The results are the focus of the visit! The most imprecise thing about precision medicine is the turnaround time.
- Ladies & gentlemen, my stepdaughter is amazing! Congrats, Mya!!🔥🔥
00:00 - My top 5 #ASCO18 abstracts to check in advanced NSCLC track, both a list & a video w/my explanation giving context for their significance. Check it out. Next will be my top 5 for stage I-III NSCLC, SCLC, & meso. bit.ly/JW5AdvNSCLC (pls like, comment, & subscribe!) #LCSM
- "Maybe one day, once I have decades of experience as a doctor and further training in my area of specialization, I will be able to speak about health matters with the tone of authority of the average naturopath." How to Counter the Circus of Pseudoscience nyti.ms/2Eb5ArT
- Interesting piece, suggesting we need to take COVID-19 VERY seriously & cancel everything in the foreseeable future. theatlantic.com/ideas/archive/…














